(Q50619591)

English

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

scientific article published on 24 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. (English)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

vector-borne disease

0 references

author name string

Roderick S Tang

1

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Richard R Spaete

2

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Mark W Thompson

3

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Mia MacPhail

4

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Jeanne M Guzzetta

5

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Patricia C Ryan

6

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Keith Reisinger

7

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Patricia Chandler

8

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Milo Hilty

9

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Robert E Walker

10

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Margarita M Gomez

11

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Genevieve A Losonsky

12

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

language of work or name

0 references

publication date

24 September 2008

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

26

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

6373-6382

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

50

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.09.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.09.018

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

1 reference

Europe PubMed Central

16 March 2018

http://europepmc.org/abstract/MED/18822334

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50619591&oldid=1775333365"